Mon May 4 08:56:55 SGT 2015  
SINGAPORE
HAIR™
    Hair loss, Singapore (SG)

Hair loss, Singapore (SG)

Summary

Hair loss, Singapore (SG) @singaporehair_com: Hair loss treatment clinic, Singapore

Description

Advertisement: Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
SHIM CLINIC
168 Bedok South Avenue 3 #01-473
Singapore 460168
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: Hair loss, Singapore (SG)
Opening Hours
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.

References


Latest News

Efficacy of Oral Etoposide in Pretreated Metastatic Breast Cancer: A Multicenter Phase 2 Study
Fri, 01 May 2015 05:00:00 +0100 | Medicine
Abstract: No standard chemotherapy has been defined for metastatic breast cancer (MBC) patients pretreated with anthracyclines and taxanes. A multicenter phase 2 study was conducted to evaluate the safety and efficacy of oral etoposide in patients with MBC.

Alopecia syphilitica diffusa
Fri, 01 May 2015 00:00:00 +0100 | Infection
(Source: Infection)

Congenital complex corneal choristoma associated with unilateral bony calvarial defects, subcutaneous nodules, and alopecia
Thu, 30 Apr 2015 00:00:00 +0100 | Journal of American Association for Pediatric Ophthalmology and Strabismus
We present a 3-day-old boy with the constellation of left-sided congenital complex corneal choristoma, limbal dermoid, ipsilateral bony skull defects, and bilateral subcutaneous vascularized nodules with overlying alopecia and scalp nevi. To our knowledge this is the first case of complex choristoma involving the presence of associated bony calvarial defects. This presentation may contribute to a greater understanding of the systemic findings associated with the condition. Furthermore, it may shed light on the possible syndromic spectrum associated with complex choristoma and its underlying pathophysiology. (Source: Journal of American Association for Pediatric Ophthalmology and Strabismus)

Trichoscopic Hair Evaluation in Patients with Ectodermal Dysplasia
Thu, 30 Apr 2015 00:00:00 +0100 | The Journal of Pediatrics
Hair abnormalities in ectodermal dysplasia may be difficult to identify. Among 16 patients with ectodermal dysplasia trichoscopy (hair dermoscopy) revealed predominance of pilosebaceous units with 1 hair (69%), abnormalities of hair shaft pigmentation (gray hair with single dark hairs, 56%), pili torti, trichothiodystrophy, trichorrhexis nodosa, and rarely, cicatricial alopecia. (Source: The Journal of Pediatrics)

Abstract P1-15-21: Safety of eribulin mesylate and concomitant palliative radiotherapy for metastatic breast cancer: A single-center experience
Thu, 30 Apr 2015 00:00:00 +0100 | Cancer Research
Conclusions. Our clinical practice experience supports the evidence that eribulin has clinical activity and is characterized by a manageable safety profile, also when combined to palliative RT. Concomitant treatment is feasible also in patients heavily pretreated, and with poor performance status.

Abstract P3-10-02: Gemcitabine with cisplatin or paclitaxel in metastatic triple-negative breast cancer
Thu, 30 Apr 2015 00:00:00 +0100 | Cancer Research
Conclusions:

Abstract P3-10-09: A Phase II trial of doxil, carboplatin and bevacizumab in metastatic triple negative breast cancer and molecular correlates of response
Thu, 30 Apr 2015 00:00:00 +0100 | Cancer Research
Conclusions. Results demonstrate that the combination of doxil, carboplatin, and bevacizumab is an active and well-tolerated regimen in previously untreated, metastatic, triple negative breast cancer. We anticipated presentation of additional genomic tumor profiling results that may yield insights into markers of sensitivity and mechanism of resistance to anthracycline and/or platinum.

Abstract P5-15-17: National survey of long-term recovery from chemotherapy-induced hair loss in patients with breast cancer
Thu, 30 Apr 2015 00:00:00 +0100 | Cancer Research
Background: Altered appearance due to chemotherapy is a very distressing adverse event and can remain unrecovered for a long time after chemotherapy. To clarify the current status of appearance change and its support systems, we conducted a national questionnaire survey of patients with breast cancer who had received chemotherapy in Japan. Here, we report on the long-term recovery of scalp hair loss during and after chemotherapy.

Abstract P5-19-08: IMMU-132, a potential new antibody-drug conjugate (ADC) for the treatment of triple-negative breast cancer (TNBC): Preclinical and initial clinical results
Thu, 30 Apr 2015 00:00:00 +0100 | Cancer Research
Despite major advances in breast cancer treatment, TNBC, which comprises approximately 15% of all breast cancer cases, continues to have a poor prognosis, with an increased risk of recurrence and mortality. IMMU-132 is a new ADC targeting Trop-2, an antigen found in high prevalence in many epithelial cancers, including TNBC, and conjugated to SN-38, a topoisomerase inhibitor and active metabolite of irinotecan, at a high drug:antibody ratio (7.6:1). Studies in mice bearing human pancreatic tumor xenografts (Capan-1) have shown IMMU-132 remains intact in the serum until internalized within the tumor cell where SN-38 is released (pH dependent), resulting in selective cancer cell death. IMMU-132 was found to deliver >120-fold higher amount of SN-38 to xenografted tumors than irinotecan. In an...

Abstract P5-19-27: IMMU-132, a new antibody-drug conjugate (ADC) against Trop-2, as a novel therapeutic for patients with relapsed/refractory, metastatic, triple-negative breast cancer (TNBC): Results from Phase I/II clinical trial (NCT01631552)
Thu, 30 Apr 2015 00:00:00 +0100 | Cancer Research
Conclusions: Based on laboratory and initial clinical results, IMMU-132 is an ADC that selectively delivers a topoisomerase I inhibitor to cancer cells without the need for enrichment by a companion diagnostic. It is safe, well-tolerated, with preliminary evidence of encouraging efficacy in heavily-pretreated pts with relapsed/refractory metastatic TNBC. Randomized Phase III and combination trials are being planned.